Floatz logo

Flavopiridol

Refractory Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)Phase 2Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Refractory Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Benadryl
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BB
Everolimus
OHSU Knight Cancer Institute
Phase 2BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2BB

View all 32 →

Same molecule, other indications

Flavopiridol is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
70 / 100
View asset →
Untreated Adult Acute Myeloid LeukemiaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →